Clinical Trials Logo

HIV Infection clinical trials

View clinical trials related to HIV Infection.

Filter by:

NCT ID: NCT00246610 Completed - HIV Infection Clinical Trials

Safety Of VIRACEPT® 625mg Administered To HIV-Infected Women During Pregnancy

Start date: March 2006
Phase: Phase 4
Study type: Interventional

This study is an evaluation of the safety of 625 mg formulation when administered to HIV-infected pregnant women from their second trimester through six weeks postpartum. The study will also evaluate the pharmacokinetics of VIRACEPT

NCT ID: NCT00244712 Completed - HIV Infection Clinical Trials

Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV

HEAT
Start date: July 2005
Phase: Phase 4
Study type: Interventional

This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine) and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used in combination with KALETRA (lopinavir/ritonavir) over 96 weeks

NCT ID: NCT00242840 Completed - HIV Infection Clinical Trials

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

Start date: June 2003
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.

NCT ID: NCT00234975 Completed - HIV Infection Clinical Trials

Safety of Lopinavir/Ritonavir (Kaletra) in HIV/HCV Co-infected Subjects vs Baseline Liver Biopsy Metavir Score

Start date: October 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate clinical response and safety of a Kaletra containing antiretroviral treatment regimen in HIV positive subjects with HCV coinfection.

NCT ID: NCT00234923 Completed - HIV Infection Clinical Trials

Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral NaŃ—ve Patients

MONARK
Start date: August 2003
Phase: Phase 3
Study type: Interventional

The purpose of this pilot study is to obtain a preliminary assessment of the antiviral activity and tolerability of Kaletra single agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm

NCT ID: NCT00234910 Completed - HIV Infection Clinical Trials

Efficacy of Simplified Two Drug Kaletra Regimen vs. Kaletra Triple Drug Standard of Care Regimen in Treatment naïve HIV Infected Patients

KALEAD
Start date: January 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to obtain a preliminary assessment of the antiviral activity and tolerability of simplified Kaletra dual agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm.

NCT ID: NCT00226434 Completed - Tuberculosis Clinical Trials

Early vs Late Introduction of Antiretroviral Therapy in HIV-infected Patients With Tuberculosis (ANRS 1295 CAMELIA)

Start date: January 2006
Phase: Phase 3
Study type: Interventional

In Cambodia the prevalence of both tuberculosis (TB) and Human Immunodeficiency Virus (HIV) infection is high. Data suggest that aggressive management of HIV infection, which includes Anti-Retroviral Therapy (HAART) during treatment of TB, decreases both morbidity and mortality. On the other hand, the use of HAART for patients with TB may cause severe complications due to drug-drug interactions, and occasionally a temporary exacerbation of symptoms. These reactions may be particularly severe when HAART is started soon after the start of TB treatment. The proposed study aims to determine the optimal time to initiate HAART in previously untreated HIV-infected adult patients with TB and low CD4 cell counts.

NCT ID: NCT00225303 Completed - HIV Infection Clinical Trials

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

Start date: March 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determinate the effectiveness, safety and tolerability (how well the body accepts the drug) of an investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) called TMC125.

NCT ID: NCT00225082 Completed - HIV Infection Clinical Trials

SNAP: Switching Nucleoside Analogues Protocol - Lipoatrophy and Mitochondrial Function

Start date: November 2004
Phase: N/A
Study type: Observational

HIV infected subjects receiving antiretroviral treatment for greater than 6 years with be evaluated for clinical lipoatrophy and mitochondrial function after switching nucleoside analogues from stavudine (d4T) to tenofovir treatment and after 4. Hypothesis: Tenofovir therapy will increase peripheral fat content as assessed by DEXA and mitochondrial function at 48 weeks.

NCT ID: NCT00225017 Completed - HIV Infection Clinical Trials

Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study

SABAR
Start date: June 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the change in brachial artery reactivity in HIV-infected subjects with elevated lipid levels who are switched to an atazanavir containing antiretroviral regimen